Association between molecular classification and prognosis, adjusted on known prognostic factors
| Model 1 | Univariate analyses | Multivariate analyses | ||||
| Number of patients | Number of events | HR (95% CI)* | p value* | Adjusted HR (95% CI)† | Adjusted p value† | |
| FIGO stage | ||||||
| I–II | 86 | 15 | 1 | 1 | ||
| III–IV | 35 | 17 | 3.26 (1.60 to 6.63) | 0.001 | 2.35 (1.10 to 5.02) | 0.029 |
| Histological grade‡ | ||||||
| Low grade | 90 | 16 | 1 | 1 | ||
| High grade | 35 | 18 | 4.32 (2.16 to 8.61) | <0.001 | 1.47 (0.61 to 3.53) | 0.390 |
| Molecular groups | ||||||
| Non-TP53-mutated classified§ | 88 | 16 | 1 | 1 | ||
| TP53-mutated classified | 30 | 18 | 6.15 (3.00 to 12.6) | <0.001 | 5.54 (2.30 to 13.4) | <0.001 |
| Model 2 | Number of patients | Number of events | HR (95% CI)* | p value* | Adjusted HR (95% CI)¶ | Adjusted p value¶ |
| Clinical risk of relapse** | ||||||
| Low/intermediate/high-intermediate risk | 72 | 11 | 1 | 1 | ||
| High risk | 40 | 13 | 2.50 (1.09 to 5.71) | 0.031 | 1.76 (0.73 to 4.23) | 0.208 |
| Molecular groups | ||||||
| Non-TP53-mutated classified§ | 83 | 14 | 1 | 1 | ||
| TP53-mutated classified | 22 | 10 | 4.71 (2.00 to 11.1) | <0.001 | 3.92 (1.59 to 9.64) | 0.003 |
HR (95% CI): hazard ratio with 95% confidence interval, estimated using the Cox logistic regression model. p value estimated using the Cox logistic regression model.
Model 1 included all patients with available data for each variable considered in the model (N=116 patients).
Model 2 included only patients without advanced/metastatic disease (N=105 patients), in order to estimate the association between TP53/CNH-like tumors and event-free survival, independently of clinical risk of relapse.
*All values displayed are estimated in univariable analysis.
†All values displayed are adjusted on the three variables included in the multivariable model 1.
‡Low grade tumors included grade 1 and 2 endometrioid carcinomas. High grade tumors included grade 3 endometrioid carcinomas and type 2 carcinomas.
§Non-TP53-mutated classified tumors: belonging to the POLE/ultramutated-like, MSI/hypermutated-like (mismatch repair deficient), and not otherwise specified groups, compared to the TP53-mutated molecular group.
¶All values displayed are adjusted on the two variables included in the multivariable model 2. Model 2 included all patients with available data for each variable considered in the model.
**Based on ESMO-ESGO-ESTRO consensus.3 4
CNH, copy-number-high; EFS, event-free survival; ESMO-ESGO-ESTRO, European Society for Medical Oncology-European Society of Gynaecological Oncology-European SocieTy for Radiotherapy & Oncology; MSI, microsatellite instability.